Replay, a genome writing company reprogramming biology by writing, designing and delivering big DNA, and Miltenyi Biotec, a global provider of products and services for biomedical research and cellular therapy, entered into a licensing and manufacturing agreement to support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy targeting the tumor-associated neoantigen, PRAME. Under the agreement, Syena, the oncology-focused engineered cell therapy product c...